A new prodrug form of Affibody molecules (pro-Affibody) is selectively activated by cancer-associated proteases.
about
Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment.Protease substrate profiling using bacterial display of self-blocking affinity proteins and flow-cytometric sorting.Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy.Functionalized protein nanocages as a platform of targeted therapy and immunodetection.Staphylococcus carnosus: from starter culture to protein engineering platform.
P2860
A new prodrug form of Affibody molecules (pro-Affibody) is selectively activated by cancer-associated proteases.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
A new prodrug form of Affibody ...... y cancer-associated proteases.
@en
type
label
A new prodrug form of Affibody ...... y cancer-associated proteases.
@en
prefLabel
A new prodrug form of Affibody ...... y cancer-associated proteases.
@en
P2860
P1476
A new prodrug form of Affibody ...... y cancer-associated proteases.
@en
P2093
Andreas Jonsson
Lisa Sandersjöö
P2860
P2888
P304
P356
10.1007/S00018-014-1751-8
P50
P577
2014-10-07T00:00:00Z